Brief: Ovid Therapeutics Reports Business Update, Fourth Quarter And Full Year 2022 Financial Results

Ovid Therapeutics

13/03/2023 12:22

March 13 (Reuters) - Ovid Therapeutics Inc  OVID.O :
    * OVID THERAPEUTICS REPORTS BUSINESS UPDATE, FOURTH QUARTER
AND
FULL YEAR 2022 FINANCIAL RESULTS
    * Q4 LOSS PER SHARE $0.16
    * CURRENT CASH RUNWAY EXPECTED TO FUND OPERATIONS INTO FIRST
HALF
OF 2025
    * TAKEDA'S GUIDANCE ON SOTICLESTAT REMAINS UNCHANGED;
ANTICIPATES
REGULATORY FILINGS IN ITS FY 2024
    * OV329 PHASE 1 TRIAL IS PROGRESSING ON TRACK
    * Q4 EARNINGS PER SHARE VIEW $-0.18, REVENUE VIEW $0.00 --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3pJD1Z 
Further company coverage:  OVID.O 

 ((Reuters.Briefs@thomsonreuters.com;;))